Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia-Reference-Cited by-同舟云学术

Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia

Published:2019-05-23 Issue:10 Volume:3 Page:1581-1585
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

McMahon Christine M.¹^ORCID,Canaani Jonathan²,Rea Bryan³,Sargent Rachel L.⁴^ORCID,Qualtieri Julianne N.⁵,Watt Christopher D.⁵,Morrissette Jennifer J. D.⁵,Carroll Martin¹⁶,Perl Alexander E.¹^ORCID

Affiliation:

1. Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA;

2. Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel;

3. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA;

4. Janssen Research and Development, Spring House, PA;

5. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA; and

6. Philadelphia Veterans Affairs Medical Center, Philadelphia, PA

Abstract

Key Points Gilteritinib induces 2 distinct marrow responses in FLT3-mutated AML: responses with and without differentiation. Ongoing clonal hematopoiesis is ubiquitous during gilteritinib therapy and may promote genetic evolution and drug resistance.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/10/1581/1632340/advances029496.pdf

Reference17 articles.

1. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study;Perl;Lancet Oncol,2017

2. Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clincial activity in multiply relapsed FLT3-ITD and D835 AML;Cortes;J Clin Oncol,2016

3. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia;Smith;Nature,2012

4. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial;Cortes;Lancet Oncol,2018

5. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML;Cortes;Blood,2018

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia;Cancers;2024-01-29

2. FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia;Leukemia;2024-01-05

3. Differentiating Acute Myeloid Leukemia Stem Cells/Blasts;Reference Module in Biomedical Sciences;2024

4. Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia;Frontiers in Pharmacology;2023-10-26

5. Differentiation Syndrome in Acute Leukemia: APL and Beyond;Cancers;2023-09-28